Home > Search Results

Results: 12

Clear

Bibliographic details: von Tresckow B, Engert A.  [Brentuximab vedotin. A new targeted approach for the treatment of relapsed or refractory Hodgkin's lymphoma patients]. [Brentuximab Vedotin. Ein neuer, zielgerichteter Ansatz zur Behandlung rezidivierter oder refraktarer Hodgkin-Patienten.] Onkologe 2014; 20(5): 464-469

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

The drug nivolumab (trade name: Opdivo) has been approved in Germany since November 2016 for the treatment of Hodgkin's lymphoma. It is a treatment option for adults if their cancer returns after stem cell transplantation and antibody treatment with brentuximab vedotin, or if these treatments were not effective enough.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: April 20, 2017

The objective of this review was to assess the efficacy of the treatment of lymphoma in children with antibody therapy in terms of survival, relapse rates and response to treatment, compared with therapy not including antibody treatment. Furthermore, it aimed to evaluate the effects of antibody therapy on quality of life and side effects.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Expert-reviewed information summary about the treatment of childhood Hodgkin lymphoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: August 31, 2017

Expert-reviewed information summary about the treatment of mycosis fungoides (including Sézary syndrome).

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: July 12, 2017

Expert-reviewed information summary about the treatment of mycosis fungoides (including Sézary Syndrome).

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: September 7, 2017

Expert-reviewed information summary about the treatment of adult Hodgkin lymphoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: July 5, 2017

Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: August 3, 2017

Non-Hodgkin's lymphoma is the sixth most common cancer in the UK. There are many different subtypes of the disease, with markedly different clinical courses and requirements for therapy. Diagnosing non-Hodgkin's lymphoma and the precise subtype is challenging, and optimising the diagnostic process is central to improved management. Significant improvements in our understanding of the biology of non-Hodgkin's lymphoma have contributed to improved diagnosis and also allowed for more targeted therapies.

NICE Guideline - National Guideline Alliance (UK).

Version: July 2016

Expert-reviewed information summary about the treatment of adult non-Hodgkin lymphoma

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: August 11, 2017

Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: August 18, 2017

Different levels of service are needed to manage haematological cancers, depending on the particular cancer in question. Because of the increased complexity of care and changes in the levels of care from those specified in the 2003 NICE cancer service guidance on improving outcomes in haematological cancers, an update was needed.

NICE Guideline - National Collaborating Centre for Cancer (UK).

Version: May 2016

Systematic Reviews in PubMed

See all (27)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...